Seagate Technology Holdings PLC vs Twist Bioscience Corp — how do they compare? Seagate Technology Holdings PLC trades at $781.4 (market cap $176.19B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Seagate Technology Holdings PLC is far larger — about 17.5× Twist Bioscience Corp's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Seagate Technology Holdings PLC for 41 Days and Twist Bioscience Corp for 27 Days on average.
| STX | TWST | |
|---|---|---|
Market Cap | $176.19B | $10.08B |
Volume | 5,061,875 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $1.09K | $205.00 |
52-Week Low | $211.63 | $25.45 |
Typical Hold Time | 41 Days | 27 Days |
Enterprise Value | $178.34B | $10.01B |
Dividend Yield | 0.38% | — |
Signals from Pluang's Aura AI — not financial advice
Seagate Technology (STX) trades at $807.34, up 0.21% with recent volatility driven by AI storage competition concerns. The stock shows strong profitability with 26.11% net margin and 371.53% ROE, though valuation ratios appear elevated (P/E 55.74, P/B 81.31). Recent earnings consistently beat expectations, with Q2 2026 EPS of $5.71 surpassing the $5.10 estimate. Technical indicators show bearish momentum with support at $794 and resistance at $816.
Outlook remains cautiously optimistic given strong AI-driven storage demand and analyst consensus price target of $1,130. Key risks include increased competition from Toshiba's planned production expansion and potential margin compression. The company's negative shareholder equity and high debt levels warrant monitoring, though projected 2026 revenue growth to $12.2B with $3.2B net income suggests continued operational strength.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →